A meta-analysis of 9 clinical trials found tirzepatide does not increase pancreatitis risk but is associated with nearly double the risk of gallbladder or biliary disease compared to placebo or basal insulin.
1.97x gallbladder/biliary disease riskTirzepatide was associated with nearly double the risk of composite gallbladder or biliary disease compared to placebo or basal insulin across 9 clinical trials
What the researchers found
Across 9 RCTs with 9,871 participants (6,828 tirzepatide, 3,043 controls), tirzepatide was not associated with a significantly increased risk of pancreatitis (RR 1.46, 95% CI 0.59–3.61, I² = 0.0%).
However, the composite of gallbladder or biliary disease was significantly elevated with tirzepatide compared to placebo or basal insulin (RR 1.97, 95% CI 1.14–3.42, I² = 0.0%). When broken down individually, the risks of cholelithiasis (gallstones), cholecystitis (gallbladder inflammation), and biliary diseases were not individually significant.
Why it matters
As tirzepatide becomes one of the most prescribed medications for diabetes and obesity worldwide, understanding its safety profile is essential. Rapid weight loss from any cause can increase gallbladder disease risk, and GLP-1-class drugs have previously raised concerns about pancreatitis. This meta-analysis provides reassurance on the pancreatitis front but raises a clinically important flag about gallbladder and biliary complications that clinicians and patients should be aware of.
How the study worked
This was a systematic review and meta-analysis following PROSPERO registration (CRD42023412400). Researchers searched Embase, PubMed, and the Cochrane Library through March 2023 for randomized controlled trials comparing tirzepatide to placebo or active comparators (basal insulin, GLP-1 agonists) in people with type 2 diabetes or obesity. Heterogeneity was assessed using I² and Cochran's Q test. A fixed effects model was used to estimate safety outcomes including pancreatitis, composite gallbladder/biliary disease, cholecystitis, and cholelithiasis.
What this study cannot tell us
The relatively small number of pancreatitis events across trials means the study may be underpowered to detect a true increase in risk (wide confidence interval: 0.59–3.61). The composite gallbladder/biliary outcome was significant but individual components were not, suggesting the signal may be driven by the aggregation. The search only included trials through March 2023, missing more recent large-scale studies. Fixed effects models were used, which may not be appropriate if there is undetected heterogeneity. The control groups varied (placebo, insulin, GLP-1 agonists), introducing potential comparison inconsistencies.
How to read the evidence
This is a systematic review and meta-analysis of randomized controlled trials, which represents a high level of evidence. The pre-registered protocol, low heterogeneity, and inclusion of only RCTs strengthen the findings, though the relatively small number of safety events limits the precision of the estimates.
When this study was published
Published in 2023 with data through March 2023, this study captures the early tirzepatide trial era. More recent and larger trials may provide updated safety data that could refine these estimates.
The bigger picture
Gallbladder complications have emerged as a consistent safety signal across the GLP-1 and GIP/GLP-1 drug class, likely related to the rapid weight loss these drugs promote. This meta-analysis extends that concern specifically to tirzepatide, the newest entrant in the class. As these drugs move into broader populations — including non-diabetic obesity treatment — monitoring for gallbladder disease becomes even more important since the patient population is expanding well beyond the traditionally studied groups.
Questions still open
- Does the gallbladder risk with tirzepatide differ based on the rate of weight loss, and could slower titration mitigate this risk?
- Is the gallbladder signal specific to tirzepatide's dual GIP/GLP-1 mechanism, or is it comparable to single GLP-1 agonists like semaglutide?
- With more recent and larger trial data now available, does the pancreatitis safety profile of tirzepatide still hold up?
Common questions
Should I worry about pancreatitis if I'm taking tirzepatide?
Why might tirzepatide increase gallbladder problems?
Read the original research
Safety issues of tirzepatide (pancreatitis and gallbladder or biliary disease) in type 2 diabetes and obesity: a systematic review and meta-analysis.
Frontiers in endocrinology, 14, 1214334
Citation
Zeng, Qingyue; Xu, Jiao; Mu, Xingyu; Shi, Yi; Fan, Hong; Li, Shuangqing. (2023). Safety issues of tirzepatide (pancreatitis and gallbladder or biliary disease) in type 2 diabetes and obesity: a systematic review and meta-analysis.. Frontiers in endocrinology, 14, 1214334. https://doi.org/10.3389/fendo.2023.1214334